<p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）預計將在 2026 年 2 月 5 日星期四市場開盤前發佈其 2026 年第三季度財報。分析師預計該公司將宣佈每股收益為 1.16 美元，季度收入為 2.86932 億美元。Prestige Consumer Healthcare 已將其 2026 財年的每股收益指導目標設定為 4.540-4.580。鼓勵個人訪問該公司即將發佈的 2026 年第三季度財報概覽頁面，以獲取有關定於 2026 年 2 月 5 日東部時間上午 8:30 的電話會議的最新信息。</p>
<p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）最近於 11 月 6 日星期四發佈了其財報。該公司報告季度每股收益為 1.07 美元，超出市場共識預期的 0.97 美元，超出幅度為 0.10 美元。Prestige Consumer Healthcare 的淨利潤率為 18.09%，股本回報率為 12.43%。該公司季度收入為 2.7411 億美元，而分析師預期為 2.5714 億美元。去年同期，該公司每股收益為 1.09 美元。與去年同期相比，該公司的季度收入下降了 3.4%。分析師平均預計 Prestige Consumer Healthcare 在當前財年將發佈每股收益 5 美元，下一財年也將發佈每股收益 5 美元。</p>
<h2>Prestige Consumer Healthcare 股票表現</h2>
<p>Prestige Consumer Healthcare 的股票在星期四開盤價為 63.18 美元。該公司的 50 日移動平均線為 62.32 美元，200 日移動平均線為 64.48 美元。Prestige Consumer Healthcare 的 1 年最低價為 57.25 美元，1 年最高價為 90.04 美元。該公司的流動比率為 3.70，速動比率為 2.51，債務與股本比率為 0.55。該公司的市值為 30.4 億美元，市盈率為 15.68，市盈增長比率為 2.01，貝塔值為 0.40。</p>
<h2>Prestige Consumer Healthcare 內部活動</h2>
<p>在其他新聞中，副總裁 Jeffrey Zerillo 於 11 月 28 日星期五出售了 719 股公司的股票。股票以平均價格 60.00 美元出售，總價值為 43,140.00 美元。交易完成後，該副總裁持有公司股票 42,329 股，價值 2,539,740 美元。這代表其持股比例下降了 1.67%。該交易已在向美國證券交易委員會（SEC）提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司股票的 1.40%。</p>
<h2>機構投資者對 Prestige Consumer Healthcare 的看法</h2>
<p>機構投資者最近增加或減少了對該公司的持股。AQR Capital Management LLC 在第一季度將其在 Prestige Consumer Healthcare 的股份增加了 11.9%。AQR Capital Management LLC 目前持有 30,056 股公司股票，價值 2,558,000 美元，此前在上個季度又收購了 3,200 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增加了對 Prestige Consumer Healthcare 的持股 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 29,490 股公司股票，價值 2,535,000 美元，此前在該期間又購買了 1,289 股。高盛集團在第一季度將其在 Prestige Consumer Healthcare 的持股增加了 28.4%。高盛集團目前持有 546,672 股公司股票，價值 46,997,000 美元，此前在上個季度又購買了 120,965 股。Jane Street Group LLC 在第一季度將其在 Prestige Consumer Healthcare 的持股增加了 204.0%。Jane Street Group LLC 目前持有 104,802 股公司股票，價值 9,010,000 美元，此前在上個季度又購買了 70,330 股。最後，Geneos Wealth Management Inc.在第一季度將其在 Prestige Consumer Healthcare 的持股增加了 92.8%。Geneos Wealth Management Inc.目前持有 559 股公司股票，價值 48,000 美元，此前在該期間又購買了 269 股。99.95% 的股票由機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票研究分析師對該公司進行了評估。Oppenheimer 在 10 月 21 日星期二的研究報告中將 Prestige Consumer Healthcare 的目標價格從 82.00 美元下調至 72.00 美元，並對該公司給予了 “跑贏大盤” 的評級。Zacks Research 在 11 月 10 日星期一的報告中將 Prestige Consumer Healthcare 的評級從 “強烈賣出” 上調至 “持有”。Jefferies Financial Group 在 10 月 27 日星期一的研究報告中將 Prestige Consumer Healthcare 的目標價格從 75.00 美元下調至 71.00 美元，並對該公司給予了 “持有” 評級。Canaccord Genuity Group 在 11 月 7 日星期五的研究報告中將 Prestige Consumer Healthcare 的目標價格從 100.00 美元下調至 88.00 美元，並對該股票給予了 “買入” 評級。最後，Weiss Ratings 在 1 月 22 日星期四的研究報告中重新發布了對 Prestige Consumer Healthcare 股票的 “持有（c）” 評級。四位分析師對該股票給予了買入評級，四位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，Prestige Consumer Healthcare 目前的平均評級為 “適度買入”，平均目標價格為 85.33 美元。</p>
<p><strong>查看我們對 Prestige Consumer Healthcare 的最新分析</strong></p>
<h2>關於 Prestige Consumer Healthcare</h2>
<p>（獲取免費報告）</p>
<p>Prestige Consumer Healthcare, Inc 是一家領先的品牌非處方（OTC）醫療產品製造和營銷公司。該公司專注於開發、收購和商業化多樣化的非處方藥物組合，以滿足常見消費者健康需求，包括疼痛緩解、感冒和咳嗽、消化健康、眼部護理、皮膚護理和女性健康。</p>
<p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部護理）、Chloraseptic（喉嚨痛緩解）、Dramamine（暈動病）、Rolaids（抗酸劑）、Monistat（女性健康）、BC Powder（疼痛緩解）、Little Remedies（兒童感冒和氣體緩解）和 TheraTears（乾眼治療）。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，而非 Prestige Consumer Healthcare</li>
<li>家族信託如何幫助保護您的財富</li>
<li>請勿刪除，立即閲讀</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>用這四個簡單步驟讓您的銀行賬户 “防聯儲”</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地被激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資$1,000 到 Prestige Consumer Healthcare 嗎？</h2>
<p>在您考慮 Prestige Consumer Healthcare 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Prestige Consumer Healthcare 並不在名單上。</p>
<p>雖然 Prestige Consumer Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

普雷斯蒂奇

<p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH）將於 2 月 5 日公佈其 2026 年第三季度財報，預計每股收益為 1.16 美元，收入為 2.8693 億美元。該公司此前報告的每股收益為 1.07 美元，超出預期。分析師預計 2026 財年的每股收益指導為 4.540-4.580。該股票開盤價為 63.18 美元，市值為 30.4 億美元。最近的內部交易活動包括副總裁 Jeffrey Zerillo 出售股份，機構投資者已增加其持股。分析師的評級各不相同，目標價格範圍在 71.00 美元至 88.00 美元之間</p>

<p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.16 per share and revenue of $286.9320 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Individuals are encouraged to explore the company's upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）預計將在 2026 年 2 月 5 日星期四市場開盤前發佈其 2026 年第三季度財報。分析師預計該公司將宣佈每股收益為 1.16 美元，季度收入為 2.86932 億美元。Prestige Consumer Healthcare 已將其 2026 財年的每股收益指導目標設定為 4.540-4.580。鼓勵個人訪問該公司即將發佈的 2026 年第三季度財報概覽頁面，以獲取有關定於 2026 年 2 月 5 日東部時間上午 8:30 的電話會議的最新信息。</p>
</div><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same period last year, the firm earned $1.09 EPS. The business's quarterly revenue was down 3.4% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）最近於 11 月 6 日星期四發佈了其財報。該公司報告季度每股收益為 1.07 美元，超出市場共識預期的 0.97 美元，超出幅度為 0.10 美元。Prestige Consumer Healthcare 的淨利潤率為 18.09%，股本回報率為 12.43%。該公司季度收入為 2.7411 億美元，而分析師預期為 2.5714 億美元。去年同期，該公司每股收益為 1.09 美元。與去年同期相比，該公司的季度收入下降了 3.4%。分析師平均預計 Prestige Consumer Healthcare 在當前財年將發佈每股收益 5 美元，下一財年也將發佈每股收益 5 美元。</p>
</div><h2>Prestige Consumer Healthcare Stock Performance</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 股票表現</h2>
</div><p>Shares of Prestige Consumer Healthcare stock opened at $63.18 on Thursday. The company has a 50 day moving average of $62.32 and a 200-day moving average of $64.48. Prestige Consumer Healthcare has a 1-year low of $57.25 and a 1-year high of $90.04. The company has a current ratio of 3.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. The company has a market cap of $3.04 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 2.01 and a beta of 0.40.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare 的股票在星期四開盤價為 63.18 美元。該公司的 50 日移動平均線為 62.32 美元，200 日移動平均線為 64.48 美元。Prestige Consumer Healthcare 的 1 年最低價為 57.25 美元，1 年最高價為 90.04 美元。該公司的流動比率為 3.70，速動比率為 2.51，債務與股本比率為 0.55。該公司的市值為 30.4 億美元，市盈率為 15.68，市盈增長比率為 2.01，貝塔值為 0.40。</p>
</div><h2>Insider Activity at Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 內部活動</h2>
</div><p>In other news, VP Jeffrey Zerillo sold 719 shares of the company's stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares of the company's stock, valued at $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，副總裁 Jeffrey Zerillo 於 11 月 28 日星期五出售了 719 股公司的股票。股票以平均價格 60.00 美元出售，總價值為 43,140.00 美元。交易完成後，該副總裁持有公司股票 42,329 股，價值 2,539,740 美元。這代表其持股比例下降了 1.67%。該交易已在向美國證券交易委員會（SEC）提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司股票的 1.40%。</p>
</div><h2>Institutional Investors Weigh In On Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>機構投資者對 Prestige Consumer Healthcare 的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its stake in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock valued at $2,558,000 after acquiring an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Prestige Consumer Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock valued at $2,535,000 after purchasing an additional 1,289 shares during the period. Goldman Sachs Group Inc. raised its position in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Jane Street Group LLC raised its position in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock worth $9,010,000 after purchasing an additional 70,330 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares during the period. 99.95% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該公司的持股。AQR Capital Management LLC 在第一季度將其在 Prestige Consumer Healthcare 的股份增加了 11.9%。AQR Capital Management LLC 目前持有 30,056 股公司股票，價值 2,558,000 美元，此前在上個季度又收購了 3,200 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增加了對 Prestige Consumer Healthcare 的持股 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 29,490 股公司股票，價值 2,535,000 美元，此前在該期間又購買了 1,289 股。高盛集團在第一季度將其在 Prestige Consumer Healthcare 的持股增加了 28.4%。高盛集團目前持有 546,672 股公司股票，價值 46,997,000 美元，此前在上個季度又購買了 120,965 股。Jane Street Group LLC 在第一季度將其在 Prestige Consumer Healthcare 的持股增加了 204.0%。Jane Street Group LLC 目前持有 104,802 股公司股票，價值 9,010,000 美元，此前在上個季度又購買了 70,330 股。最後，Geneos Wealth Management Inc.在第一季度將其在 Prestige Consumer Healthcare 的持股增加了 92.8%。Geneos Wealth Management Inc.目前持有 559 股公司股票，價值 48,000 美元，此前在該期間又購買了 269 股。99.95% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities research analysts have weighed in on the company. Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an &#34;outperform&#34; rating for the company in a research note on Tuesday, October 21st. Zacks Research raised Prestige Consumer Healthcare from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, November 10th. Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a &#34;hold&#34; rating for the company in a research report on Monday, October 27th. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $85.33.</p>
<div class="lb-trans"><p>幾位股票研究分析師對該公司進行了評估。Oppenheimer 在 10 月 21 日星期二的研究報告中將 Prestige Consumer Healthcare 的目標價格從 82.00 美元下調至 72.00 美元，並對該公司給予了 “跑贏大盤” 的評級。Zacks Research 在 11 月 10 日星期一的報告中將 Prestige Consumer Healthcare 的評級從 “強烈賣出” 上調至 “持有”。Jefferies Financial Group 在 10 月 27 日星期一的研究報告中將 Prestige Consumer Healthcare 的目標價格從 75.00 美元下調至 71.00 美元，並對該公司給予了 “持有” 評級。Canaccord Genuity Group 在 11 月 7 日星期五的研究報告中將 Prestige Consumer Healthcare 的目標價格從 100.00 美元下調至 88.00 美元，並對該股票給予了 “買入” 評級。最後，Weiss Ratings 在 1 月 22 日星期四的研究報告中重新發布了對 Prestige Consumer Healthcare 股票的 “持有（c）” 評級。四位分析師對該股票給予了買入評級，四位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，Prestige Consumer Healthcare 目前的平均評級為 “適度買入”，平均目標價格為 85.33 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Prestige Consumer Healthcare</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Prestige Consumer Healthcare 的最新分析</strong></p>
</div><h2>About Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>關於 Prestige Consumer Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare, Inc 是一家領先的品牌非處方（OTC）醫療產品製造和營銷公司。該公司專注於開發、收購和商業化多樣化的非處方藥物組合，以滿足常見消費者健康需求，包括疼痛緩解、感冒和咳嗽、消化健康、眼部護理、皮膚護理和女性健康。</p>
</div><p>Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).</p>
<div class="lb-trans"><p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部護理）、Chloraseptic（喉嚨痛緩解）、Dramamine（暈動病）、Rolaids（抗酸劑）、Monistat（女性健康）、BC Powder（疼痛緩解）、Little Remedies（兒童感冒和氣體緩解）和 TheraTears（乾眼治療）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Prestige Consumer Healthcare</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Prestige Consumer Healthcare</li>
<li>家族信託如何幫助保護您的財富</li>
<li>請勿刪除，立即閲讀</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>用這四個簡單步驟讓您的銀行賬户 “防聯儲”</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地被激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&amp;Symbol=PBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資$1,000 到 Prestige Consumer Healthcare 嗎？</h2>
</div><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Prestige Consumer Healthcare 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Prestige Consumer Healthcare 並不在名單上。</p>
</div><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prestige Consumer Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

普雷斯蒂奇消費者醫療保健公司（PBH）預計將在週四公佈季度財報